Targets › G6PC
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2026.
Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum. Forms with the glucose-6-phosphate transporter (SLC37A4/G6PT) the complex responsible for glucose production in the terminal step of glycogenolysis and gluconeogenesis. (UniProt, P35575)
Open in Phaseline: the race on G6PC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ModernaTX | mRNA-3745 mRNA therapy encoding glucose-6-phosphatase | G6PC | Phase 1 | Glycogen Storage Disease | Nov 2026 |
Glycogen Storage Disease (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.